Biotech's surge pushes Bay Area companies — including a Covid drug hopeful — toward collective $1 billion in fresh funds

Three IPOs and four follow-on offerings are planned by companies working on treatments for a range of diseases, from cancer to Covid.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.